佐多雷塞Zoldonrasib RMC-9805

KRAS G12D INHIBITOR 18;(2S)-2-环戊基-2-((S)-7-((2R,3R)-3-环丙基-1-甲氧基氮丙啶-2-羰基)-2,7-二氮杂螺[4.4]壬烷-2-基)-N-((22S,63S,4S)-12-(5-(4-环丙基哌嗪-1-基)-2-((S)-1-甲氧基乙基)吡啶-3-基)-10,10-二甲基-5,7-二氧代-11-(2,2,2-三氟乙基)-61,62,63,64,65,66-六氢-11H-8-氧杂-2(4,2)-吗啉-1(5,3)吲哚-6(1,3)-哒嗪环十一烷-4-基)乙酰胺;化合物 RMC-9805;KRAS G12D抑制剂18;KRAS G12D抑制剂18,10 MM DMSO 溶液;(2S)-2-环戊基-2-[(5S)-2-[(2R,3R)-3-环丙基-1-甲基氮杂环丙烷-2-羰基]-2,7-二氮杂螺[4.4]壬烷-7-基]-N-[(6S,8S,14S)-21-[5-(4-环丙基哌嗪-1-基)-2-[(1S)-1-甲氧基乙基]吡啶-3-基]-18,18-二甲基-9,15-二氧代-22-(2,2,2-三氟乙基)-5,16-二氧杂-2,10,22,28-四氮杂五环[18.5.2.12,6.110,14.023,27]二十九烷-1(26),20,23(27),24-四烯-8-基]乙酰胺;(2S)-2-环戊基-2-((S)-7-((2R,3R)-3-环丙基-1-甲氧基氮丙啶-2-羰基)-2,7-二氮杂螺[4.4]壬烷-2-基)-N-((22S,63S,4S)-12-(5-(4-环丙基哌嗪-1-基)-2-((S)-1-甲氧基乙基)吡啶-3-基)-10,10-二甲基-5,7-二氧代-11-(2,2,2-三氟;RMI-9805

RMI-5921;KRAS G12D inhibitor 18|||KRAS G12D IN 18;(2S)-2-Cyclopentyl-2-((S)-7-((2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl)-2,7-diazaspiro[4.4]nonan-2-yl)-N-((22S,63S,4S)-12-(5-(4-cyclopropylpiperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-11-(2,2,2-trifluoroethyl)-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-morpholina-1(5,3)-indola-6(1,3)-pyridazinacycloundecaphane-4-yl)acetamide;(2S)-2-cyclopentyl-2-[(5S)-7-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-2-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetraazapentacyclo[18.5.2.12,?.11?,1?.023,2?]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide;KRAS G12D inhibitor 18, 10 mM in DMSO;RMC-9850;(2S)-2-Cyclopentyl-2-[(5S)-2-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-7-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide;Zoldonrasib/RMI-5921